Basic Information
| RNALocate ID: | RLID:11004233 |
| RNA Symbol: | hsa-miR-1226-5p |
| Localization: | Exosome |
RNA Information
| RNA Name: | hsa-miR-1226-5p |
| RNA ID: | miRBase:MIMAT0005576 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 25242326 |
| Tissue/Cell Line: | B cell lymphoma cell lines|EBV-transformed lymphoblastoid B cells |
| Method: | Next-generation RNA sequencing |
| Description: | Although the miRNA distribution in exosomal fractions is clearly influenced by cellular miRNA abundance, we identified a subset of miRNAs that were discordantly distributed between cells and exosomes (false discovery rate [FDR] < 0.05; Tables S1B and S1C). |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:11004231 | Exosome | Pooled sera | 27278097 |
| RLID:11004232 | Exosome | Jurkat-derived T cell line (J77cl20) | 21505438 |
| RLID:11004234 | Microvesicle | Seminal plasma | 23539611 |
| RLID-D:11000748 | Microvesicle | Fibroblasts|Mesenchymal stem cells | |
| RLID-D:11001634 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-1226-5p | Oral squamous cell carcinoma | MNDR-E-MI-05445 |
| MNDR | hsa-miR-1226-5p | B cell lymphoma of malt type | MNDR-E-MI-05446 |
| MNDR | hsa-miR-1226-5p | Lymphoma | MNDR-E-MI-05447 |
| MNDR | hsa-miR-1226-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-05448 |
| MNDR | hsa-miR-1226-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-05449 |
| MNDR | hsa-miR-1226-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-05450 |
| MNDR | hsa-miR-1226-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-05451 |
| MNDR | hsa-miR-1226-5p | Her2-receptor positive breast cancer | MNDR-E-MI-05452 |
| MNDR | hsa-miR-1226-5p | Breast cancer luminal | MNDR-E-MI-05453 |
| MNDR | hsa-miR-1226-5p | Prostate cancer | MNDR-E-MI-05454 |
| MNDR | hsa-miR-1226-5p | Gastric cancer | MNDR-E-MI-05455 |
| MNDR | hsa-miR-1226-5p | Intracranial aneurysm | MNDR-E-MI-05456 |
| MNDR | hsa-miR-1226-5p | Moyamoya disease | MNDR-E-MI-05457 |
| MNDR | hsa-miR-1226-5p | Parkinson disease | MNDR-E-MI-05458 |
| MNDR | hsa-miR-1226-5p | Basal-like breast cancer | MNDR-E-MI-05459 |
| MNDR | hsa-miR-1226-5p | Pancreatic cancer | MNDR-E-MI-05460 |
| MNDR | hsa-miR-1226-5p | Melanoma | MNDR-E-MI-05461 |
| MNDR | hsa-miR-1226-5p | Colon cancer | MNDR-E-MI-05462 |
| MNDR | hsa-miR-1226-5p | Familial ovarian cancer | MNDR-E-MI-05463 |
| MNDR | hsa-miR-1226-5p | Glioblastoma | MNDR-E-MI-05464 |
| MNDR | hsa-miR-1226-5p | Malignant glioma | MNDR-E-MI-05465 |
| MNDR | hsa-miR-1226-5p | Osteosarcoma | MNDR-E-MI-05466 |
| MNDR | hsa-miR-1226-5p | Infarction middle cerebral artery | MNDR-E-MI-05467 |
| MNDR | hsa-miR-1226-5p | Liver cancer | MNDR-E-MI-05468 |
| MNDR | hsa-miR-1226-5p | Lung squamous cell carcinoma | MNDR-E-MI-05469 |
| MNDR | hsa-miR-1226-5p | Lung adenocarcinoma | MNDR-E-MI-05470 |
| MNDR | hsa-miR-1226-5p | Pancreatic adenocarcinoma | MNDR-E-MI-05471 |
| MNDR | hsa-miR-1226-5p | Esophageal cancer | MNDR-E-MI-05472 |
| MNDR | hsa-miR-1226-5p | Lung small cell carcinoma | MNDR-E-MI-05473 |
| MNDR | hsa-miR-1226-5p | Hepatocellular carcinoma | MNDR-E-MI-05474 |
| MNDR | hsa-miR-1226-5p | Familiar ovarian carcinoma | MNDR-E-MI-05475 |
| MNDR | hsa-miR-1226-5p | B-cell lymphoma | MNDR-E-MI-05476 |
| MNDR | hsa-miR-1226-5p | Colorectal cancer | MNDR-E-MI-05477 |
| MNDR | hsa-miR-1226-5p | Nasopharynx carcinoma | MNDR-E-MI-05478 |
| MNDR | hsa-miR-1226-5p | Multiple myeloma | MNDR-E-MI-05479 |
| MNDR | hsa-miR-1226-5p | Nasopharyngeal cancer | MNDR-E-MI-05480 |
| MNDR | hsa-miR-1226-5p | Breast cancer her3+ negative | MNDR-E-MI-05481 |
TOP